Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

September 21, 2018 by Alan Khadavi

Inhaled Triple Therapy for Respiratory Disease

Inhaled triple therapy  is being recommended for patients with severe chronic obstructive pulmonary disease (COPD) as a step up therapy.  Inhaled triple therapy consists of 3 ingredients;

  1. Inhaled corticosteroids
  2. Long acting muscarinic antagonists (LAMA)
  3. Long acting Beta agonists (LABAs)

This is considered a step up therapy for patients with frequent exacerbations.  Two recent studies were conducted that strengthened the evidence to support this recommendation.  The first one published in the New England Journal of Medicine, showed the inhaled triple therapy (fluticasone furoate, umeclidinium and vilanterol) for 52 weeks, decreased the rate of of moderate to severe exacerbations compared to dual therapy alone.  However, the risk of pneumonia increased.  The second study published in the Lancet, compared inhaled triple therapy (beclomethasone dipropionate, glycopyrronium and formoterol fumarate with dual therapy.  After 1 year, triple inhaled therapy decreased the rate of moderate and severe exacerbations.  Notably, triple inhaled therapy with this combination was not associated with an increased risk of pneumonia.

The findings of these 2 trials support use of inhaled triple therapy to prevent COPD exacerbations in patients with severe COPD in whom dual bronchodilator therapy fails.

In previous blog posts, we discussed two new triple therapies that were approved.

Trelegy, New Asthma Triple Therapy to be Released by GSK

Trimbow Triple Combination For COPD and Asthma by Chiesi

Both of these inhaled triple therapies were approved for COPD alone.  Currently the treatment of choice for moderate to severe asthma patients is dual therapy (inhaled corticosteroids and a long acting Beta agonist).  Medications in this class are Breo, Dulera, Symbicort, AirDuo Respiclick and Advair.

AirDuo Respiclick, New Asthma Combo Maintenance Inhaler

Breo for Asthma now available as a once daily treatment

Although these inhaled triple therapy medications are not currently FDA approved for asthma, adding a LAMA to dual therapy is currently being used for asthma patients not well controlled.

It may be a matter of time before these inhaled triple therapy medications are approved for asthma.  For severe asthma patients, recently several biological injectable medications were approved.

Cinqair (Reslizumab) for Eosinophil Disorders (formerly Cinquil)

New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma

Fasenra (Benralizumab) for Severe Asthma

If you suffer from COPD or asthma and it is not well controlled and you are having frequent and severe exacerbations, speak to your doctor and see what medications may be best for you.

Filed Under: Asthma, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page